Medexus Pharmaceuticals Inc (MDP) Earnings Dates, Call Summary & Reports

Compare

68 Followers

Earnings Data

Report Date

Jun 30, 2026

Before Open (Confirmed)

Period Ending

2026 (Q4)

Consensus EPS Forecast

-0.02

Last Year’s EPS

-0.03

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2026

Earnings Call Date:Feb 11, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call highlighted meaningful early commercial traction for GRAFAPEX (formulary uptake, reorder rates, improving patient demand and a FY26 revenue outlook of $11M–$12M), margin improvements, strong operating cash generation, reduced net debt and cost savings initiatives (IXINITY). Offsetting these positives were year-over-year declines in total net revenue, adjusted EBITDA and net income driven by Rupall generic competition, the return of Gleolan, and launch investments that have so far slightly exceeded GRAFAPEX product-level revenue. Management emphasized improving trends, cash flow strength, and financing flexibility that position the company to scale commercialization. Overall, the positives around GRAFAPEX momentum and liquidity improvements balance the near-term earnings and revenue headwinds, leading to a neutral assessment.

Company Guidance

Management guided that GRAFAPEX will be accretive to quarterly operating cash flow starting in fiscal Q4 ’26 and is expected to generate product‑level net revenue of $11–$12 million for fiscal 2026; through the nine months ended Dec 31, 2025 they recognized $8.2M of GRAFAPEX product‑level revenue versus $8.5M invested in the launch year‑to‑date, Q3 ’26 product‑level net revenue was $2.0M (underlying patient demand $2.6M), and they expect patient demand in fiscal Q4 ’26 of roughly $3–$4M (prior quarters: Q1 $2.2M, Q2 $2.1M, Q3 $2.6M) which, given wholesaler inventory, implies Q4 product‑level net revenue of $3–$4M; adoption metrics include 32% of the 180 U.S. transplant centers (57 centers) having ordered with a 77% reorder rate, roughly one‑third on formulary/one‑third under review/one‑third in process, and an adult/pediatric split of ~85%/15% (Medicare NTAP add‑on ≈ $21,000 covering ~30% of adult patients); SG&A related to GRAFAPEX is expected to rise modestly back toward $3–$4M and nearer $4M in fiscal ’27; company‑level Q3 results and balance‑sheet metrics cited alongside this guidance were: net revenue $25.3M (vs $30.0M y/y), gross profit $13.6M (gross margin 53.6% vs 50.7% y/y), adjusted EBITDA $4.5M (vs $5.8M), operating income $1.7M (vs $2.1M), net income $0.1M (vs $0.7M), operating cash flow $7.8M (vs $6.7M), average cash from operations $4.3M/quarter since launch, cash on hand $15M (Dec 31, 2025), net debt $10.4M (down from $13.2M Mar 31, 2025), 201,500 shares repurchased, a new credit facility that reduced quarterly principal repayments from $3.3M to $0.5M, a $1.2M committed IXINITY process investment (to be paid in fiscal ’26) and a 30% reduction in IXINITY product‑level COGS since fiscal Q1 ’21.

GRAFAPEX Early Commercial Adoption

32% of 180 U.S. transplant centers (57 institutions) have ordered GRAFAPEX and 77% of those centers have reordered; product-level patient demand rebounded strongly in January 2026 and product-level net revenue for the 9 months ending Dec 31, 2025 totaled $8.2M.

GRAFAPEX Revenue and Guidance

GRAFAPEX product-level net revenue in fiscal Q3 '26 was $2.0M (patient demand $2.6M); company expects GRAFAPEX product-level net revenue of $11M–$12M for fiscal year 2026 and forecasts underlying patient demand in fiscal Q4 '26 of approximately $3M–$4M.

Accretive Outlook and Cash Flow Contribution

Management expects GRAFAPEX to be accretive to quarterly operating cash flow starting in fiscal Q4 '26; average cash from operations of $4.3M per quarter in the 4 quarters since launch and quarterly operating cash flow of $7.8M in fiscal Q3 '26 (up from $6.7M in Q3 '25, +16.4%).

Improved Gross Margin

Gross margin improved to 53.6% in fiscal Q3 '26 from 50.7% in fiscal Q3 '25 (increase of 2.9 percentage points), despite a decrease in gross profit dollars.

IXINITY Manufacturing Cost Reductions

Ongoing IXINITY process improvement initiative reduced product-level cost of goods by 30% comparing fiscal Q3 '26 to fiscal Q1 '21, supporting margin improvement and prompting an additional $1.2M process investment commitment.

Balance Sheet and Liquidity Actions

Net debt decreased to $10.4M at Dec 31, 2025 from $13.2M at Mar 31, 2025 (decrease $2.8M); new senior secured credit facility with lower principal repayments (from $3.3M/quarter under prior facility to $0.5M/quarter) provides flexibility; cash on hand was $15M at Dec 31, 2025.

Product-Specific Demand Tailwinds

Rasuvo experienced a 17% increase in patient unit demand YoY in fiscal Q3 '26 following competitor withdrawal; pediatric uptake of GRAFAPEX is strong due to fertility and toxicity benefits.

Capital Allocation and Shareholder Return

Company fully repaid the remaining regulatory milestone payment for GRAFAPEX using cash on hand and initiated an issuer bid, repurchasing 201,500 shares to date.

Medexus Pharmaceuticals Inc (TSE:MDP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:MDP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jun 30, 2026	2026 (Q4)	-0.02 / -	-0.027	―	―	―
Feb 11, 2026	2026 (Q3)	-0.03 / 0.00	0.041	―		―
Nov 12, 2025	2026 (Q2)	-0.03 / -0.01	0	―	―	―
Aug 12, 2025	2026 (Q1)	-0.04 / 0.03	0.109	-75.00% (-0.08)	―	―
Jun 25, 2025	2025 (Q4)	-0.09 / -0.03	0.042	-164.52% (-0.07)	―	―
Feb 05, 2025	2025 (Q3)	0.05 / 0.04	-0.027	250.00% (+0.07)	―	―
Nov 07, 2024	2025 (Q2)	0.03 / 0.00	-0.068	―	―	―
Aug 07, 2024	2025 (Q1)	0.07 / 0.11	0.041	166.67% (+0.07)	―	―
Jun 25, 2024	2024 (Q4)	-0.02 / 0.04	0.464	-90.88% (-0.42)	―	―
Feb 07, 2024	2024 (Q3)	0.08 / -0.03	-0.096	71.43% (+0.07)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:MDP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 11, 2026	C$2.81	C$2.74	-2.49%
Nov 12, 2025	C$2.70	C$2.69	-0.37%
Aug 12, 2025	C$2.75	C$2.67	-2.91%
Jun 25, 2025	C$3.35	C$3.15	-5.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Medexus Pharmaceuticals Inc (TSE:MDP) report earnings?

Medexus Pharmaceuticals Inc (TSE:MDP) is schdueled to report earning on Jun 30, 2026, Before Open (Confirmed).

What is Medexus Pharmaceuticals Inc (TSE:MDP) earnings time?

Medexus Pharmaceuticals Inc (TSE:MDP) earnings time is at Jun 30, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:MDP EPS forecast?

TSE:MDP EPS forecast for the fiscal quarter 2026 (Q4) is -0.02.